US Bancorp DE increased its holdings in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 9.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,651 shares of the medical research company's stock after buying an additional 1,655 shares during the quarter. US Bancorp DE's holdings in IQVIA were worth $4,264,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in IQV. Riverview Trust Co purchased a new position in IQVIA during the first quarter valued at approximately $25,000. Quent Capital LLC lifted its holdings in IQVIA by 271.8% during the first quarter. Quent Capital LLC now owns 145 shares of the medical research company's stock valued at $34,000 after purchasing an additional 106 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in IQVIA by 243.2% during the first quarter. EverSource Wealth Advisors LLC now owns 151 shares of the medical research company's stock valued at $35,000 after purchasing an additional 107 shares in the last quarter. Total Clarity Wealth Management Inc. purchased a new position in IQVIA during the second quarter valued at approximately $41,000. Finally, Prospera Financial Services Inc purchased a new position in IQVIA during the first quarter valued at approximately $44,000. Hedge funds and other institutional investors own 86.77% of the company's stock.
Get IQVIA alerts:Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on IQV. Morgan Stanley lifted their price objective on shares of IQVIA from $255.00 to $260.00 and gave the company an "overweight" rating in a research report on Friday, July 22nd. SVB Leerink initiated coverage on shares of IQVIA in a report on Friday, July 15th. They issued an "outperform" rating and a $256.00 target price on the stock. Deutsche Bank Aktiengesellschaft lowered their target price on shares of IQVIA from $290.00 to $270.00 in a report on Tuesday, October 18th. Credit Suisse Group initiated coverage on shares of IQVIA in a report on Wednesday, August 24th. They issued an "outperform" rating and a $300.00 target price on the stock. Finally, Barclays lowered their target price on shares of IQVIA from $235.00 to $215.00 and set an "overweight" rating on the stock in a report on Thursday, October 6th. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and an average target price of $269.94.
IQVIA Trading Down 0.3 %
Shares of IQV opened at $174.04 on Monday. IQVIA Holdings Inc. has a twelve month low of $165.75 and a twelve month high of $285.61. The company has a market cap of $32.46 billion, a P/E ratio of 29.06, a P/E/G ratio of 1.64 and a beta of 1.36. The company has a current ratio of 0.96, a quick ratio of 0.96 and a debt-to-equity ratio of 2.36. The company's fifty day simple moving average is $203.28 and its 200-day simple moving average is $213.46.IQVIA (NYSE:IQV – Get Rating) last announced its earnings results on Thursday, July 21st. The medical research company reported $2.25 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.04. IQVIA had a net margin of 8.21% and a return on equity of 30.21%. The business had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.49 billion. During the same quarter in the prior year, the firm posted $1.94 earnings per share. The business's revenue for the quarter was up 3.0% on a year-over-year basis. As a group, analysts expect that IQVIA Holdings Inc. will post 9.39 EPS for the current year.
IQVIA Profile
(Get Rating)
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- Time to Hit Up Hasbro Stock for the Holiday Season
- Should Proctor and Gamble be a Staple in Your Portfolio?
- 3 Fundamentally Sound Mid-Caps to Keep on the Watch List
- Leveraged ETFs, A Bad Investment But Great for Trading
- Should Investors Raise a Glass to Boston Beer Company?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Get Rating).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.